SWM
AGIO icon

SeaCrest Wealth Management’s Agios Pharmaceuticals AGIO Stock Holding History

SeaCrest Wealth Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11
Closed -$1K – 2128
2018
Q4 		$1K Hold
11
– – ﹤0.01% 1969
2018
Q3 		$1K Buy
+11
New +$885 ﹤0.01% 2125

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SeaCrest Wealth Management's AGIO Position: Q1 2019 in Review

SeaCrest Wealth Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2019, closing a stake of 11 shares — an estimated $1K sold.

SeaCrest Wealth Management first reported a position in AGIO in Q3 2018 and held it in 2 quarters. The position peaked at $1K in Q4 2018. 201 funds tracked by Wall St. Rank hold AGIO as of Q1 2019.

  • SeaCrest Wealth Management reported no remaining Agios Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 11 Agios Pharmaceuticals shares in Q1 2019, an estimated $1K.
  • SeaCrest Wealth Management first reported a position in Agios Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • SeaCrest Wealth Management's Agios Pharmaceuticals position peaked at $1K in Q4 2018.
  • 201 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2019.

Based on SeaCrest Wealth Management's 13F filing for Q1 2019, filed 10 May 2019.